Actively Recruiting
Addressing Genomic Disparities in Cancer Survivors
Led by Rutgers, The State University of New Jersey · Updated on 2025-10-28
428
Participants Needed
2
Research Sites
160 weeks
Total Duration
On this page
Sponsors
R
Rutgers, The State University of New Jersey
Lead Sponsor
G
Georgetown University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to increase genetic education and genetic testing for hereditary cancer risk among Black cancer survivors. The study will: 1. Test the effectiveness of a chatbot intervention (also called relational agent, or RA) vs. enhanced usual care (EUC) on engagement in genetic education and requests for genetic testing. 2. Evaluate the impact of the chatbot vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes). 3. Explore the ways (methods) that influence how participants experience the intervention. 4. Explore the feasibility of incorporating a Family Sharing Portal (FSP) for participants who receive a positive test result, to facilitate family communication of these test results and genetic testing of first-degree biological relatives after they have received genetic education by the RA. The main questions this study aims to answer are which group - the chatbot (RA) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education. Participants will be randomly assigned to either the chatbot (RA) group or EUC group. This means each participant has an equal chance of being placed in either group, just like flipping a coin. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the chatbot (RA) group and the EUC group to see which may request more GT (genetic testing) and which group engages more with genetic education.
CONDITIONS
Official Title
Addressing Genomic Disparities in Cancer Survivors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 80 years
- Self-identify as Black or African American
- At least 6 months since diagnosis of breast, ovarian, uterine, prostate, colorectal, or pancreatic cancer
- Have not had genetic testing for hereditary cancer
- Received care at one of the participating sites within the past five years
- Meet National Comprehensive Cancer Network criteria for germline genetic testing
- Able to read and speak English
- Capable of providing informed consent
- Have internet access via smartphone, tablet, or computer
- Comfortable using a computer or mobile phone independently to access information
You will not qualify if you...
- Do not speak English
- Unable to access the internet
- Have previously undergone germline genetic testing for hereditary cancer risk or had genetic counseling and declined testing
- Unable to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States, 20007
Actively Recruiting
2
Rutgers Cancer Institute
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
Research Team
E
Erin Speiser, PhD, MA
CONTACT
J
Julie Chapman Greene, PhD, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here